# A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Source: https://onco.cc/trials/renaviv/  
OnCo record `renaviv` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Abexinostat in renal cell carcinoma, now recruiting.

## Summary

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) is a phase 3 interventional study registered as NCT03592472, led by Xynomic Pharmaceuticals, and recruiting on the registry. Official title: A Randomised, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV). Planned enrolment is 413 participants (estimated). The study started in 2018-07-17 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: RENAVIV
- Tags: ctgov-ingest
- Registry id: NCT03592472
- Phase: 3
- Setting: A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)
- Sponsor: Xynomic Pharmaceuticals
- Enrolled: 413

## Sources

- ClinicalTrials.gov NCT03592472: https://clinicaltrials.gov/study/NCT03592472

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Abexinostat](https://onco.cc/drugs/abexinostat/)
- companies: [Xynomic Pharmaceuticals](https://onco.cc/companies/xynomic-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/renaviv.json